Gastroesophageal Junction Adenocarcinoma Clinical Trials

22 studies are recruiting for gastroesophageal junction adenocarcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

   This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a sui…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Oncology Institute of Hope and Innovation, Cerritos, California

   Locations

   105 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT06324357 on ClinicalTrials.gov

2. Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

   This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Precision NextGen Oncology, Beverly Hills, California

   Locations

   8 in total

   Run by

   Neonc Technologies, Inc.

   See if you can join NCT06047379 on ClinicalTrials.gov

3. A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

   This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric or gastroesophageal junction (GEJ) that is locally advanced and cannot …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ironwood Cancer and Research Centers Chandler Ii, Chandler, Arizona

   Locations

   95 in total

   Run by

   BeOne Medicines

   See if you can join NCT07043400 on ClinicalTrials.gov

4. A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma

   The purpose of this study is to find out whether adding the drug 2141-V11 to standard treatment (anti-PD-1 immunotherapy with or without 5-FU) is a safe treatment approach for participants with advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering at Basking Ridge (Limited protocol activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07818018 on ClinicalTrials.gov

5. A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

   This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced o…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Anchorage, Alaska

   Locations

   302 in total

   Run by

   AstraZeneca

   See if you can join NCT06764875 on ClinicalTrials.gov

6. A Study of KK2269 in Adult Participants With Solid Tumors

   This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors for which no standard therapy is available will be enrolled in Part 1. In Part 1, the primary obje…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Arizona, Scottsdale, Arizona

   Locations

   32 in total

   Run by

   Kyowa Kirin Co., Ltd.

   See if you can join NCT06266299 on ClinicalTrials.gov

7. Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

   The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GE…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Phoenix, Arizona

   Locations

   311 in total

   Run by

   AstraZeneca

   See if you can join NCT07431281 on ClinicalTrials.gov

8. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

   The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope National Medical Center, Duarte, California

   Locations

   31 in total

   Run by

   Pfizer

   See if you can join NCT07090499 on ClinicalTrials.gov

9. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

   This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the earl…

   Stage

   Not phased

   Ages

   40 to 75

   Site

   Anchorage Associates in Radiation Medicine, Anchorage, Alaska

   Locations

   745 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT05334069 on ClinicalTrials.gov

10. Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

    This study is being done to answer the following questions: Can we lower the chance of your gastric cancer from growing or spreading by administering paclitaxel chemotherapy directly into your abdominal cavity in addition to chemotherapy given through a vein in your arm? Will administering paclitax…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California

    Locations

    78 in total

    Run by

    ECOG-ACRIN Cancer Research Group

    See if you can join NCT07001748 on ClinicalTrials.gov

11. NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

    The purpose of this Phase I study is to determine the recommended phase 2 dose (RP2D) and safety profile of NBTXR3 activated by radiation therapy with concurrent chemotherapy for the treatment of patients with esophageal adenocarcinoma. NBTXR3 is a drug that when activated by radiation therapy, may…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT04615013 on ClinicalTrials.gov

12. A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

    This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic Hospital, Phoenix, Arizona

    Locations

    48 in total

    Run by

    Seagen, a wholly owned subsidiary of Pfizer

    See if you can join NCT06131840 on ClinicalTrials.gov

13. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

    This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Alaska Oncology and Hematology, Anchorage, Alaska

    Locations

    158 in total

    Run by

    Seagen, a wholly owned subsidiary of Pfizer

    See if you can join NCT04389632 on ClinicalTrials.gov

14. A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

    This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocar…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    27 in total

    Run by

    Toray Industries, Inc

    See if you can join NCT06038578 on ClinicalTrials.gov

15. Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

    This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends an…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Mayo Clinic in Florida, Jacksonville, Florida

    Run by

    Mayo Clinic

    See if you can join NCT06265285 on ClinicalTrials.gov

16. Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

    The goal of this study is to learn about of the research study drug, telomelysin (OBP-301), in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer. The main question it aims to answer is whether this combination is safe and effective in this ty…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York

    Locations

    2 in total

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT06340711 on ClinicalTrials.gov

17. Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

    This phase II clinical trial tests how well robotic cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in treating patients with gastric cancer that has spread to the tissue that lines the wall of the abdominal cavity (peritoneum). Gastric cancer is the third leading cause of cance…

    Stage

    Phase 2

    Ages

    18 to 80

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT05753306 on ClinicalTrials.gov

18. Folfox+Irinotecan+Chemort In Esophageal Cancer

    In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal junction or esophagogastric cancer This research study involves the following study intervention: - Lipos…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT04656041 on ClinicalTrials.gov

19. Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

    The purpose of the proposed study is to establish the safety of combining irinotecan chemotherapy with 5-FU, leucovorin/folinic acid, oxaliplatin, and docetaxel (abbreviated as the I-FLOAT study of gFOLFOXIRITAX) chemotherapies (leucovorin/folinic acid is a vitamin to make 5-FU work well).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Chicago, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT04361708 on ClinicalTrials.gov

20. APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

    To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring w…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California

    Locations

    35 in total

    Run by

    Apollomics Inc.

    See if you can join NCT03175224 on ClinicalTrials.gov

21. A Multicenter Cancer Biospecimen Collection Study

    This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent st…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Curebase, San Francisco, California

    Run by

    Cofactor Genomics, Inc.

    See if you can join NCT04510129 on ClinicalTrials.gov

22. Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

    Esophageal cancer, which has a low 5-year overall survival rate for all stages (<20%) , is increasing in incidence. Previous studies have shown that the Hedgehog (Hh) and AKT signaling pathways are activated in a significant proportion of esophageal cancers. Itraconazole, a widely used anti-fungal …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Dallas VA Medical Center, Dallas, Texas

    Run by

    Dallas VA Medical Center

    See if you can join NCT04018872 on ClinicalTrials.gov